Ernstoff, Marc S.

Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: American Society of Clinical Oncology Clinical Practice Guideline

Brahmer, J. R., Lacchetti, C., Schneider, B. J., Atkins, M. B., Brassil, K. J., Caterino, J. M., Chau, I., Ernstoff, M. S., Gardner, J. M., Ginex, P., et al. (2018) · Journal of Clinical Oncology

Cancer Immunotherapy and BiomarkersPharmacovigilance and Adverse Drug Reactions

Cited by 3,713

Nivolumab and ipilimumab versus ipilimumab in untreated melanoma

Postow, M. A., Chesney, J., Pavlick, A. C., Robert, C., Grossmann, K., McDermott, D., Linette, G. P., Meyer, N., Giguere, J. K., Agarwala, S. S., et al. (2015) · New England Journal of Medicine

Cancer Immunotherapy and BiomarkersCutaneous Melanoma Detection and Management

Cited by 2,781

Managing toxicities associated with immune checkpoint inhibitors: consensus recommendations from the Society for Immunotherapy of Cancer (SITC) Toxicity Management Working Group

on behalf of the Society for Immunotherapy of Cancer Toxicity Management Working Group, Puzanov, I., Diab, A., Abdallah, K., Bingham, C. O., Brogdon, C., Dadu, R., Hamad, L., Kim, S., Lacouture, M. E., et al. (2017) · Journal for ImmunoTherapy of Cancer

Cancer Immunotherapy and BiomarkersImmunotherapy and Immune Responses

Cited by 1,992

Ipilimumab in patients with melanoma and brain metastases: an open-label, phase 2 trial

Margolin, K., Ernstoff, M. S., Hamid, O., Lawrence, D., McDermott, D., Puzanov, I., Wolchok, J. D., Clark, J. I., Sznol, M., Logan, T. F., et al. (2012) · The Lancet Oncology

Brain Metastases and TreatmentCancer Immunotherapy and Biomarkers

Cited by 1,091

Combined nivolumab and ipilimumab versus ipilimumab alone in patients with advanced melanoma: 2-year overall survival outcomes in a multicentre, randomised, controlled, phase 2 trial

Hodi, F. S., Chesney, J., Pavlick, A. C., Robert, C., Grossmann, K. F., McDermott, D. F., Linette, G. P., Meyer, N., Giguere, J. K., Agarwala, S. S., et al. (2016) · The Lancet Oncology

Cancer Immunotherapy and BiomarkersCutaneous Melanoma Detection and Management

Cited by 968

Society for immunotherapy of cancer (SITC) clinical practice guideline on immune checkpoint inhibitor-related adverse events

Brahmer, J. R., Abu-Sbeih, H., Ascierto, P. A., Brufsky, J., Cappelli, L. C., Cortazar, F. B., Gerber, D. E., Hamad, L., Hansen, E., Johnson, D. B., et al. (2021) · Journal for ImmunoTherapy of Cancer

Cancer Immunotherapy and BiomarkersImmunotherapy and Immune Responses

Cited by 917

Management of Immunotherapy-Related Toxicities, Version 1.2019, NCCN Clinical Practice Guidelines in Oncology

Thompson, J. A., Schneider, B. J., Brahmer, J., Andrews, S., Armand, P., Bhatia, S., Budde, L. E., Costa, L., Davies, M., Dunnington, D., et al. (2019) · Journal of the National Comprehensive Cancer Network

Cancer Immunotherapy and BiomarkersImmunotherapy and Immune Responses

Cited by 570

VISTA is an immune checkpoint molecule for human T cells

Lines, J. L., Pantazi, E., Mak, J., Sempere, L. F., Wang, L., O'Connell, S., Ceeraz, S., Suriawinata, A. A., Yan, S., Ernstoff, M. S., et al. (2014) · Cancer Research

Cancer Immunotherapy and BiomarkersT-cell and B-cell Immunology

Cited by 510

Autoimmune diseases and immune-checkpoint inhibitors for cancer therapy: Review of the literature and personalized risk-based prevention strategy

Haanen, J., Ernstoff, M. S., Wang, Y., Menzies, A. M., Puzanov, I., Grivas, P., Larkin, J., Peters, S., Thompson, J. A., & Obeid, M. (2020) · Annals of Oncology

Cancer Immunotherapy and BiomarkersT-cell and B-cell Immunology

Cited by 222

Expressive Disclosure and Health Outcomes in a Prostate Cancer Population

Rosenberg, H. J., Rosenberg, S. D., Ernstoff, M. S., Wolford, G. L., Amdur, R. J., Elshamy, M. R., Bauer-Wu, S. M., Ahles, T. A., & Pennebaker, J. W. (2002) · The International Journal of Psychiatry in Medicine

Cancer survivorship and careMental Health via Writing

Cited by 179

Clinical Trials of Bispecific Antibody MDX-210 in Women with Advanced Breast or Ovarian Cancer that Overexpresses HER-2/neu

VALONE, F. H., KAUFMAN, P. A., GUYRE, P. M., LEWIS, L. D., MEMOLI, V., ERNSTOFF, M. S., WELLS, W., BARTH, R., DEO, Y., FISHER, J., et al. (1995) · Journal of Hematotherapy

Monoclonal and Polyclonal Antibodies ResearchHER2/EGFR in Cancer Research

Cited by 48